Approval · Notice of Compliance 3514 · 2003
RANITIDINE: Notice of Compliance 3514
Issued May 12, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3514
- Date
- May 12, 2003
- Company
- Pharmascience Inc.Montreal, Quebec, Canada
- Product type
- Nonprescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Admin
- Reason
- Product name change from pms-ranitidine
- Therapeutic class
- Histamine h2-receptor antagonist
- Canadian reference product
- ZANTAC (Glaxo Wellcome Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| RANITIDINE | 02245615 | Cancelled Pre Market |
Medicinal ingredients
- RANITIDINE HCL 75 MG per TAB